Redcare Pharmacy’s Logistics Bet Tests Investor Patience as Rx Growth Accelerates

Redcare Pharmacy's shares tumble as margin targets are slashed, executives depart, and heavy investment in logistics weighs on profitability despite Rx market dominance.

The online pharmacy operator is walking a tightrope between breakneck expansion and margin discipline, with its share price reflecting deep market skepticism. Redcare Pharmacy’s stock has tumbled roughly 64% from its 52-week peak of €136.20, now trading at €48.78, as a costly investment cycle and executive departures overshadow the company’s strong grip on Germany’s electronic prescription market.

A Leadership Shake-Up at a Critical Juncture

The departure of Chief Commercial Officer Dirk Brüse on April 28, 2026, for personal reasons has added an element of uncertainty just days before the company’s first-quarter earnings report. CEO Olaf Heinrich has taken direct control of commercial operations until a successor is found. This is not the only change at the top: three new supervisory board members — Anja Hendel, Max Müller, and Peter Schmid von Linstow — were appointed at the annual general meeting in mid-April, while Hendrik Krampe officially assumed the role of chief financial officer.

Krampe’s mandate is clear: expand higher-margin revenue streams such as the company’s own marketplace and retail-media services to offset the structural drag from prescription drug sales. The Rx segment now accounts for 36% of group revenue, up sharply in 2025, but its lower margins are squeezing overall profitability.

Margin Targets Slashed as Investment Spending Peaks

Redcare’s medium-term margin goal has been cut from over 8% to more than 5%, a stark admission that the current expansion phase is costing more than anticipated. For the full year 2026, management forecasts adjusted EBITDA margins of at least 2.5%, with revenue growth of 13% to 15%. The company is pouring capital into a new logistics hub in Pilsen, Czech Republic, which will add 15 million parcels of annual capacity, while automation upgrades at its main site in Sevenum aim to push total capacity to 15 million packages per year and reduce unit costs.

Once the investment cycle concludes, Redcare expects capital expenditure to fall below 2% of revenue. Until then, the balance sheet is under pressure. The stock has lost about 27% since the start of the year, though it has recovered sharply from its March low of €31.00. The relative strength index sits at 27, signaling technically oversold conditions.

Rx Dominance Provides a Buffer, but OTC Faces Headwinds

Redcare commands a 67% market share in Germany’s online prescription segment, a position reinforced by a new digital identity solution from partners ehex and D-Trust. Launched in April 2026, the technology eliminates the need for a physical institutional card, streamlining B2B access to the telematics infrastructure and lowering costs. The company expects Rx revenues to exceed €670 million in 2026.

Competition in the over-the-counter segment is intensifying. Drugstore chain dm launched its own platform, “dm-med,” in late 2025, and Redcare has trimmed its OTC growth forecast to 8% to 10%. However, potential reforms to Germany’s statutory health insurance system could provide a tailwind: higher patient co-payments of up to €15 might drive price-sensitive consumers toward online channels.

Analyst Divergence and the May 6 Test

The analyst community is split. Jefferies maintains a buy rating with a €150 price target, citing e-prescription growth and 14.2 million active customers in the first quarter. UBS stays neutral at €74, flagging a slowdown in the core OTC segment. Bankhaus Metzler’s Felix Dennl sees possible upside from healthcare policy changes. Barclays recently cut its target from €110 to €70 but retains an “overweight” rating. The average analyst price target stands at roughly €95, with seven buy recommendations and no sell calls.

All eyes are on May 6, when Redcare publishes its full first-quarter report — the first hard data since the investment cycle intensified. The numbers will reveal whether the logistics buildup and marketplace expansion are beginning to generate measurable returns, or whether the margin gap between revenue growth and profitability is widening further. For investors, that report will carry more weight than any management reshuffle.